Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRESCO-2: Fruquintinib plus best supportive care in refractory metastatic colorectal cancer
2020-000158-88Phase 3Terminated
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Fruquintinib + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Overall survival. Started Jun 2020; status: terminated.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-000158-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000158-88.